Takara Bio Deepens Losses, Maintains Full-Year Forecast and Dividend Suspension

Takara Bio Inc. ( (JP:4974) ) has issued an announcement.

Takara Bio Inc. reported nine-month results to December 31, 2025 showing net sales of ¥28.39 billion, down 3.0% year on year, and a deepening loss, with operating loss widening to ¥4.86 billion and net loss attributable to owners of the parent expanding to ¥9.62 billion. The company’s equity ratio fell to 77.4% from 92.2% at the previous fiscal year-end, net assets per share declined, and basic earnings per share swung further negative, underscoring mounting pressure on profitability and balance sheet strength.

Management kept its full-year forecast unchanged, projecting a 6.5% decline in net sales to ¥42.1 billion and a full-year net loss of ¥9.0 billion, and it also maintained guidance for no interim or year-end dividend for the year ending March 31, 2026. During the period, Takara Bio expanded its consolidation scope by adding Curio Biosciences, Inc., signaling continued strategic investment despite losses, a move that could influence its competitive positioning in advanced life science tools while near-term returns to shareholders remain constrained.

The most recent analyst rating on (JP:4974) stock is a Sell with a Yen747.00 price target. To see the full list of analyst forecasts on Takara Bio Inc. stock, see the JP:4974 Stock Forecast page.

More about Takara Bio Inc.

Takara Bio Inc. is a Japan-based biotechnology company listed on the Tokyo Stock Exchange that develops and sells research reagents, gene therapy and cell processing technologies. The company operates globally in the life sciences sector, serving academic, pharmaceutical, and industrial customers with tools and platforms for genetic analysis and biopharmaceutical development.

Average Trading Volume: 275,771

Technical Sentiment Signal: Strong Sell

Current Market Cap: Yen98.38B

For a thorough assessment of 4974 stock, go to TipRanks’ Stock Analysis page.